Owen Jones, Marco Paw Claasen, Tommy Ivanics, Woo Jin Choi, Felipe Gavaria, Luckshi Rajendran, Anand Ghanekar, Gideon Hirschfield, Aliya Gulamhusein, Chaya Shwaartz, Trevor Reichman, Blayne Amir Sayed, Markus Selzner, Mamatha Bhat, Cynthia Tsien, Elmar Jaeckel, Les Lilly, Ian D McGilvray, Mark S Cattral, Nazia Selzner, Gonzalo Sapisochin
Background Living donor liver transplantation (LDLT) offers the opportunity to decrease waitlist time and mortality for patients with AILD; autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). We compared the survival of patients with a potential live donor (pLDLT) on the waitlist vs. no potential live donor (pDDLT), on an intention-to-treat (ITT) basis. Methods Our retrospective cohort study investigated adults with AILD listed for liver transplant at our program between 2000 and 2021...
April 16, 2024: Liver Transplantation